Publications by authors named "Timothy C Hardman"

Claim this Profile
U
Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma.
Matthew Chad Eastwood, John Busby, Johan Kolmert, Javier Zurita, Sven-Erik Dahlén, Timothy Colin Hardman

ERJ Open Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges.
Charles Mundy, James Bush, Joseph Cheriyan, Ulrike Lorch, Steffan Stringer, Timothy C Hardman

Front Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control.
Xue Zeng, Jing Qing, Chi-Ming Li, Jiamiao Lu, Tracy Yamawaki, Timothy C Hardman

J Allergy Clin Immunol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future of clinical trials and drug development: 2050.
Timothy C Hardman, Rob Aitchison, Richard Scaife, Jean Edwards, Gill Slater

Drugs Context· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
Matthew C Eastwood, John Busby, David J Jackson, Ian D Pavord, Catherine E Hanratty, Timothy C Hardman

J Allergy Clin Immunol Pract· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
P Jane McDowell, John Busby, Catherine E Hanratty, Ratko Djukanovic, Ashley Woodcock, Timothy Colin Hardman

Am J Respir Crit Care Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
John Busby, John G Matthews, Rekha Chaudhuri, Ian D Pavord, Timothy C Hardman

Eur Respir J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19.
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Luydmila Yu Akhieva, Elena V Kuntsevich, Timothy C Hardman

Drugs Context· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts.
David Gomez-Cabrero, Stefan Walter, Imad Abugessaisa, Rebeca Miñambres-Herraiz, Lucia Bernad Palomares, Timothy C Hardman

Geroscience· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
Herbert Nar, Gisela Schnapp, Oliver Hucke, Timothy C Hardman, Thomas Klein

ChemMedChem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
Liam G Heaney, John Busby, Catherine E Hanratty, Ratko Djukanovic, Ashley Woodcock, Timothy C Hardman

Lancet Respir Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges.
Shahzadgai Khan, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Timothy C Hardman

Front Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.
Vladimír Tancoš, Marián Grendár, Anna Farkašová, Zdenko Huťka, Jozef Mičák, Timothy C Hardman

Pathology· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development.
Susan Reijntjes, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Timothy C Hardman

Front Pharmacol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management.
Luc Van Bortel, Hildegard Sourgens, Kerstin Breithaupt-Grögler, Henri Caplain, Yves Donazzolo, Timothy C Hardman

Front Pharmacol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ready! Aim! Fire! targeting the right medical science journal.
Timothy C Hardman, James M Serginson

Cardiovasc Endocrinol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes--the MID-Frail study: study protocol for a randomised controlled trial.
Leocadio Rodríguez-Mañas, Antony J Bayer, Mark Kelly, Andrej Zeyfang, Mikel Izquierdo, Timothy C Hardman

Trials· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New therapies to reduce low-density lipoprotein cholesterol.
Anthony S Wierzbicki, Adie Viljoen, Timothy C Hardman, Dimitri P Mikhailidis

Curr Opin Cardiol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.
Anthony S Wierzbicki, Timothy C Hardman, Adie Viljoen

Expert Opin Investig Drugs· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.
Timothy Colin Hardman, Simon William Dubrey

Diabetes Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'.
Timothy C Hardman, Peter Rutherford, Simon W Dubrey, Anthony S Wierzbicki

Curr Pharm Des· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Anthony S Wierzbicki, Scott D Purdon, Timothy C Hardman, Ranjababu Kulasegaram, Barry S Peters

Curr Med Res Opin· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction for the adverse influence of sodium-potassium cotransport on apparent sodium-lithium countertransport activity in human erythrocytes.
Timothy C Hardman, Zoë Morrish, Mayur Patel, Sylvia Chalkley, Mark I M Noble

J Pharmacol Toxicol Methods· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
Christine Falcoz, Julian M Jenkins, Carole Bye, Timothy C Hardman, Kathy B Kenney

J Clin Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter.
Anthony S Wierzbicki, Timothy C Hardman, Joseph Cheung, Michelle Lambert-Hammill, Surinda Patel

Am J Hypertens· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis